{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-104900","form_type":"8-K","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.929271+00:00","generated_at":"2026-05-17T00:49:57.961594+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ABVC BioPharma Q3 2025 licensing revenue up 230% YoY to $1.28M; total assets rise 181%","bullets":["Licensing revenue of $1.28M in Q3 2025 vs $0.39M in Q3 2024 (+230% YoY).","Total assets $21.18M (Sep 30, 2025) vs $7.54M (Dec 31, 2024); up 181%.","Property and equipment surged to $12.06M from $0.51M (+2,100%) on land buys in Taiwan.","Two land acquisitions completed in Q3: Puli ($7.67M) and Longtan ($3.3M) for R&D and API cultivation.","Company maintains asset-light licensing model with multiple CNS, ophthalmology, oncology licensing agreements."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-104900","json":"https://secwatch.observer/filing/0001213900-25-104900.json","markdown":"https://secwatch.observer/filing/0001213900-25-104900.md","text":"https://secwatch.observer/filing/0001213900-25-104900.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390025104900/0001213900-25-104900-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390025104900/ea0263481-8k_abvcbio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:49:57.961594+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}